Drug profile · INN
nirsevimab
BEYFORTUS
nirsevimab (BEYFORTUS) is a fusion glycoprotein f0 inhibitor.
EMA: approved Antiinfectives for systemic use (J06) J06BD08
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — nirsevimab
- Class
- Antiinfectives for systemic use (J06)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
nirsevimab (BEYFORTUS) is a fusion glycoprotein f0 inhibitor.
Key facts
INN nirsevimab
Brand BEYFORTUS
Mechanism Fusion glycoprotein F0 inhibitor
Target Fusion glycoprotein F0
Therapeutic class Antiinfectives for systemic use (J06)
ATC code J06BD08
Mechanism of action
Fusion glycoprotein F0 inhibitor
Primary target: Fusion glycoprotein F0
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nirsevimab?
nirsevimab (BEYFORTUS) is a fusion glycoprotein f0 inhibitor.
What is the brand name for nirsevimab?
BEYFORTUS is a marketed brand name for nirsevimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.